Document 0637
 DOCN  M9440637
 TI    Mycobacterial infections.
 DT    9404
 AU    Peloquin CA; Infectious Disease Pharmacokinetics Laboratory, National
       Jewish; Center for Immunology and Respiratory Medicine, Denver,
       Colorado; 80206.
 SO    Pharmacotherapy. 1993 Nov-Dec;13(6):634-9. Unique Identifier : AIDSLINE
       MED/94134527
 AB    Infection due to Mycobacterium tuberculosis continues to plague
       humanity. In the United States, conditions have taken a decided turn for
       the worse, with an increasing frequency of infection and the spread of
       multiple-drug-resistant strains. A number of strategies are available to
       improve the management of this epidemic. Mycobacterium avium is now
       recognized as a significant cause of morbidity and mortality in patients
       with the acquired immunodeficiency syndrome. Therapy is limited due to
       relative drug resistance, drug intolerance, and drug malabsorption;
       however, potentially useful regimens are being developed.
 DE    Antitubercular Agents/*THERAPEUTIC USE  AIDS-Related Opportunistic
       Infections/*DRUG THERAPY  Drug Resistance, Microbial  Human
       Mycobacterium avium Complex/*DRUG EFFECTS  Mycobacterium
       avium-intracellulare Infection/*DRUG THERAPY/  MORTALITY  Mycobacterium
       tuberculosis/*DRUG EFFECTS  Tuberculosis/*DRUG
       THERAPY/EPIDEMIOLOGY/MICROBIOLOGY  United States/EPIDEMIOLOGY  JOURNAL
       ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).